Baidu
map
DARU 润色咨询

DARU-Journal of Pharmaceutical Sciences

出版年份：199 年文章数：625 投稿命中率： 开通期刊会员，数据随心看

出版周期：Quarterly 自引率：1.1% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2106244, encodeId=4c4a21062443f, content=投稿12天了还是新投稿状态正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b9b6562567, createdName=ms4000000670082853, createdTime=Thu Dec 15 21:30:54 CST 2022, time=2022-12-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1089230, encodeId=346910892305b, content=一般期刊要求几张图/几个表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089229, encodeId=4e1a108922950, content=什么是协同作用？什么是相加作用？两者有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846603, encodeId=634f846603b7, content=今年的审稿人明显给力多了，意见很中肯而且可行。非常看好这个期刊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d6c5414003, createdName=ms6032332839474392, createdTime=Fri Aug 24 15:59:14 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=488173, encodeId=65b94881e383, content=全称：DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=400, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 24 20:33:00 CST 2012, time=2012-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=488172, encodeId=2e274881e278, content=到目前为止，ISI上未查到2012年文章，为何？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 24 20:32:00 CST 2012, time=2012-04-24, status=1, ipAttribution=)]
    2022-12-15 ms4000000670082853 来自广东省

    投稿12天了还是新投稿状态正常吗？

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2106244, encodeId=4c4a21062443f, content=投稿12天了还是新投稿状态正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b9b6562567, createdName=ms4000000670082853, createdTime=Thu Dec 15 21:30:54 CST 2022, time=2022-12-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1089230, encodeId=346910892305b, content=一般期刊要求几张图/几个表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089229, encodeId=4e1a108922950, content=什么是协同作用？什么是相加作用？两者有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846603, encodeId=634f846603b7, content=今年的审稿人明显给力多了，意见很中肯而且可行。非常看好这个期刊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d6c5414003, createdName=ms6032332839474392, createdTime=Fri Aug 24 15:59:14 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=488173, encodeId=65b94881e383, content=全称：DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=400, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 24 20:33:00 CST 2012, time=2012-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=488172, encodeId=2e274881e278, content=到目前为止，ISI上未查到2012年文章，为何？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 24 20:32:00 CST 2012, time=2012-04-24, status=1, ipAttribution=)]
    2021-12-29 Mia

    一般期刊要求几张图/几个表？

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2106244, encodeId=4c4a21062443f, content=投稿12天了还是新投稿状态正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b9b6562567, createdName=ms4000000670082853, createdTime=Thu Dec 15 21:30:54 CST 2022, time=2022-12-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1089230, encodeId=346910892305b, content=一般期刊要求几张图/几个表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089229, encodeId=4e1a108922950, content=什么是协同作用？什么是相加作用？两者有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846603, encodeId=634f846603b7, content=今年的审稿人明显给力多了，意见很中肯而且可行。非常看好这个期刊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d6c5414003, createdName=ms6032332839474392, createdTime=Fri Aug 24 15:59:14 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=488173, encodeId=65b94881e383, content=全称：DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=400, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 24 20:33:00 CST 2012, time=2012-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=488172, encodeId=2e274881e278, content=到目前为止，ISI上未查到2012年文章，为何？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 24 20:32:00 CST 2012, time=2012-04-24, status=1, ipAttribution=)]
    2021-12-27 msSSSSSD

    什么是协同作用？什么是相加作用？两者有什么区别？

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2106244, encodeId=4c4a21062443f, content=投稿12天了还是新投稿状态正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b9b6562567, createdName=ms4000000670082853, createdTime=Thu Dec 15 21:30:54 CST 2022, time=2022-12-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1089230, encodeId=346910892305b, content=一般期刊要求几张图/几个表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089229, encodeId=4e1a108922950, content=什么是协同作用？什么是相加作用？两者有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846603, encodeId=634f846603b7, content=今年的审稿人明显给力多了，意见很中肯而且可行。非常看好这个期刊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d6c5414003, createdName=ms6032332839474392, createdTime=Fri Aug 24 15:59:14 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=488173, encodeId=65b94881e383, content=全称：DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=400, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 24 20:33:00 CST 2012, time=2012-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=488172, encodeId=2e274881e278, content=到目前为止，ISI上未查到2012年文章，为何？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 24 20:32:00 CST 2012, time=2012-04-24, status=1, ipAttribution=)]
    2018-08-24 ms6032332839474392

    今年的审稿人明显给力多了，意见很中肯而且可行。非常看好这个期刊。

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2106244, encodeId=4c4a21062443f, content=投稿12天了还是新投稿状态正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b9b6562567, createdName=ms4000000670082853, createdTime=Thu Dec 15 21:30:54 CST 2022, time=2022-12-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1089230, encodeId=346910892305b, content=一般期刊要求几张图/几个表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089229, encodeId=4e1a108922950, content=什么是协同作用？什么是相加作用？两者有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846603, encodeId=634f846603b7, content=今年的审稿人明显给力多了，意见很中肯而且可行。非常看好这个期刊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d6c5414003, createdName=ms6032332839474392, createdTime=Fri Aug 24 15:59:14 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=488173, encodeId=65b94881e383, content=全称：DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=400, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 24 20:33:00 CST 2012, time=2012-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=488172, encodeId=2e274881e278, content=到目前为止，ISI上未查到2012年文章，为何？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 24 20:32:00 CST 2012, time=2012-04-24, status=1, ipAttribution=)]
    2012-04-24 匿名用户

    全称：DARU-JOURNAL OF PHARMACEUTICAL SCIENCES

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2106244, encodeId=4c4a21062443f, content=投稿12天了还是新投稿状态正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b9b6562567, createdName=ms4000000670082853, createdTime=Thu Dec 15 21:30:54 CST 2022, time=2022-12-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1089230, encodeId=346910892305b, content=一般期刊要求几张图/几个表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089229, encodeId=4e1a108922950, content=什么是协同作用？什么是相加作用？两者有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846603, encodeId=634f846603b7, content=今年的审稿人明显给力多了，意见很中肯而且可行。非常看好这个期刊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d6c5414003, createdName=ms6032332839474392, createdTime=Fri Aug 24 15:59:14 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=488173, encodeId=65b94881e383, content=全称：DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=400, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 24 20:33:00 CST 2012, time=2012-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=488172, encodeId=2e274881e278, content=到目前为止，ISI上未查到2012年文章，为何？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 24 20:32:00 CST 2012, time=2012-04-24, status=1, ipAttribution=)]
    2012-04-24 匿名用户

    到目前为止，ISI上未查到2012年文章，为何？

    0

共9条页码: 1/1页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分

Baidu
Baidu
map
Baidu
map
Baidu
map